Lazard Asset Management LLC cut its holdings in shares of MaxCyte, Inc. (NASDAQ:MXCT - Free Report) by 54.8% during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 163,495 shares of the company's stock after selling 197,955 shares during the period. Lazard Asset Management LLC owned 0.15% of MaxCyte worth $680,000 at the end of the most recent quarter.
Several other hedge funds and other institutional investors have also recently made changes to their positions in MXCT. SG Americas Securities LLC grew its stake in MaxCyte by 25.9% during the 4th quarter. SG Americas Securities LLC now owns 47,805 shares of the company's stock worth $199,000 after buying an additional 9,836 shares during the last quarter. Gagnon Securities LLC boosted its holdings in MaxCyte by 234.1% in the fourth quarter. Gagnon Securities LLC now owns 197,326 shares of the company's stock worth $821,000 after acquiring an additional 138,257 shares in the last quarter. China Universal Asset Management Co. Ltd. grew its stake in shares of MaxCyte by 10.7% during the fourth quarter. China Universal Asset Management Co. Ltd. now owns 22,366 shares of the company's stock worth $93,000 after acquiring an additional 2,154 shares during the last quarter. Chevy Chase Trust Holdings LLC increased its holdings in shares of MaxCyte by 0.6% during the fourth quarter. Chevy Chase Trust Holdings LLC now owns 1,339,829 shares of the company's stock valued at $5,574,000 after acquiring an additional 7,781 shares in the last quarter. Finally, Rhumbline Advisers raised its position in shares of MaxCyte by 1.6% in the 4th quarter. Rhumbline Advisers now owns 153,655 shares of the company's stock valued at $639,000 after purchasing an additional 2,402 shares during the last quarter. Hedge funds and other institutional investors own 68.81% of the company's stock.
MaxCyte Price Performance
NASDAQ:MXCT opened at $2.18 on Wednesday. The company has a 50 day moving average price of $2.68 and a 200-day moving average price of $3.55. MaxCyte, Inc. has a 1-year low of $2.10 and a 1-year high of $5.26. The firm has a market cap of $231.78 million, a price-to-earnings ratio of -6.41 and a beta of 1.38.
MaxCyte (NASDAQ:MXCT - Get Free Report) last issued its quarterly earnings results on Wednesday, May 7th. The company reported ($0.10) earnings per share (EPS) for the quarter, hitting analysts' consensus estimates of ($0.10). The company had revenue of $10.39 million for the quarter, compared to the consensus estimate of $9.05 million. MaxCyte had a negative return on equity of 16.00% and a negative net margin of 78.36%. On average, sell-side analysts anticipate that MaxCyte, Inc. will post -0.42 earnings per share for the current fiscal year.
Analyst Upgrades and Downgrades
Several equities research analysts have recently commented on MXCT shares. BTIG Research set a $6.00 price objective on shares of MaxCyte and gave the stock a "buy" rating in a research note on Wednesday, March 12th. Stifel Nicolaus lowered their price target on MaxCyte from $11.00 to $9.00 and set a "buy" rating for the company in a research report on Wednesday, March 12th.
Check Out Our Latest Stock Report on MXCT
MaxCyte Company Profile
(
Free Report)
MaxCyte, Inc, a life sciences company, discovers, develops, and commercializes next-generation cell therapies in the United States and internationally. Its products include ExPERT ATx, a static electroporation instrument for small to medium scale transfection; ExPERT STx, a flow electroporation for protein production and drug development, as well as expression of therapeutic targets for cell-based assays; ExPERT GTx, a flow electroporation for large scale transfection in therapeutic applications; and ExPERT VLx for very large volume cell-engineering.
See Also
Want to see what other hedge funds are holding MXCT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for MaxCyte, Inc. (NASDAQ:MXCT - Free Report).
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider MaxCyte, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and MaxCyte wasn't on the list.
While MaxCyte currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know? MarketBeat just compiled its list of the twelve stocks that corporate insiders are abandoning. Complete the form below to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
